File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: eGFR Improvement In Chronic Hepatitis B Patients With Telbivudine Treatment Is Independent Of Antiviral Activity

TitleeGFR Improvement In Chronic Hepatitis B Patients With Telbivudine Treatment Is Independent Of Antiviral Activity
Authors
Issue Date2013
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
Citation
The 48th Annual Meeting of the European Association for the Study of the Liver, Amsterdam, The Netherlands, 24-28 April 2013. In Journal of Hepatology, 2013, v. 58 n. Suppl. 1, p. S302, abstract no. 745 How to Cite?
AbstractBackground and Aim: It was shown, that Telbivudine treatment improved renal function assessed by estimated glomerular filtration rate (eGFR) in Chronic Hepatitis B (CHB) patients. We aimed to analyze factors potentially correlated to eGFR improvement with telbivudine. Methods: eGFR was calculated retrospectively using MDRD formula on overall ITT population (n = 687 telbivudine, n = 680 lamivudine) and subgroup of patients with reduced baseline renal function (eGFR 60–90) (n = 256 telbivudine, n = 234 lamivudine) over 2 years. Efficacy-response based subgroups were analyzed (ANCOVA model) for eGFR change. Stepwise regression (multivariate analysis) was used to model for baseline/week24 factors known to influence antiviral efficacy of telbivudine treatment on eGFR improvement (shift from 60–90 to >90 ml/min/1.72m2 eGFR) at 2 years. Results: At 2 years eGFR (LSmean) increased from baseline in telbivudine-treated patients by 8.53% compared to −0.52% in lamivudine-treated patients in the overall ITT population (p<0.001). In the subgroup of patients >50 years, eGFR increased 11.4% in telbivudine compared to -2.4% decrease in lamivudine-treated patients. Patients with baseline eGFR 60–90 ml/min/1.72m2 eGFR increased by 16.8% in telbivudine versus 3.9% n telbivudine versus treated group. eGFR improvements at 2 years were independent of baseline HBeAg status, markers of virologic response, including HBVDNA undetectable (<300 copies/ml), HBVDNA suppression (<5 logs) or virologic breakthrough/genotypic resistance at 2 years. Patients who had not achieved on-treatment HBeAg seroconversion (17.6%) or HBeAg loss (18.7%) had higher eGFR increase versus patients with HBeAg seroconversion (7.3%, p = 0.0223) or HBeAg loss (6.2%, p = 0.0035). In the stepwise regression model, no differences were observed for: baseline HBeAg status, baseline ALT (<2×ULNvs≥2×ULN), baseline HBVDNA (<9vs≥9log for HBeAg+ and <7vs≥7log for HBeAg− patients), Genotype C and undetectable HBVDNA at Week24. Telbivudine treatment (Odds ratio (OR) 2.509 (95% CI=1.663, 3.784) p<0.0001) and age (continous variable) OR 0.940 (0.923, 0.958), p = 0.0001 were the strongest significant predictors of eGFR increase. Other predictors were Caucasian race (vs Asian), OR 0.338 (0.175, 0.652), p = 0.0012 and Other vs Asian, OR 0.429 (0.183, 1.005), p = 0.0514. Conclusion: In this subanalysis of the GLOBE study, the strongest predictors of improvement on renal function during antiviral therapy in patients with compensated CHB were age and telbivudine treatment, the latter effect independent of on-treatment antiviral response.
DescriptionFulltext in: http://www2.kenes.com/liver-congress/scientific/Documents/Abstract_book.pdf
Poster Session: 07c. Viral Hepatitis B & D: Clinical (Therapy, New Compounds, Resistance)
Persistent Identifierhttp://hdl.handle.net/10722/186826
ISSN
2015 Impact Factor: 10.59
2015 SCImago Journal Rankings: 4.570

 

DC FieldValueLanguage
dc.contributor.authorGane, EJen_US
dc.contributor.authorLiaw, YFen_US
dc.contributor.authorWang, Yen_US
dc.contributor.authorLai, CLen_US
dc.contributor.authorRasenack, Jen_US
dc.contributor.authorZeuzem, Sen_US
dc.contributor.authorChan, HLYen_US
dc.contributor.authorRen, Hen_US
dc.contributor.authorDong, Yen_US
dc.contributor.authorUddin, Aen_US
dc.contributor.authorJung, MEen_US
dc.contributor.authorBosset, Sen_US
dc.contributor.authorTrylesinski, Aen_US
dc.date.accessioned2013-08-20T12:21:10Z-
dc.date.available2013-08-20T12:21:10Z-
dc.date.issued2013en_US
dc.identifier.citationThe 48th Annual Meeting of the European Association for the Study of the Liver, Amsterdam, The Netherlands, 24-28 April 2013. In Journal of Hepatology, 2013, v. 58 n. Suppl. 1, p. S302, abstract no. 745en_US
dc.identifier.issn0168-8278-
dc.identifier.urihttp://hdl.handle.net/10722/186826-
dc.descriptionFulltext in: http://www2.kenes.com/liver-congress/scientific/Documents/Abstract_book.pdf-
dc.descriptionPoster Session: 07c. Viral Hepatitis B & D: Clinical (Therapy, New Compounds, Resistance)-
dc.description.abstractBackground and Aim: It was shown, that Telbivudine treatment improved renal function assessed by estimated glomerular filtration rate (eGFR) in Chronic Hepatitis B (CHB) patients. We aimed to analyze factors potentially correlated to eGFR improvement with telbivudine. Methods: eGFR was calculated retrospectively using MDRD formula on overall ITT population (n = 687 telbivudine, n = 680 lamivudine) and subgroup of patients with reduced baseline renal function (eGFR 60–90) (n = 256 telbivudine, n = 234 lamivudine) over 2 years. Efficacy-response based subgroups were analyzed (ANCOVA model) for eGFR change. Stepwise regression (multivariate analysis) was used to model for baseline/week24 factors known to influence antiviral efficacy of telbivudine treatment on eGFR improvement (shift from 60–90 to >90 ml/min/1.72m2 eGFR) at 2 years. Results: At 2 years eGFR (LSmean) increased from baseline in telbivudine-treated patients by 8.53% compared to −0.52% in lamivudine-treated patients in the overall ITT population (p<0.001). In the subgroup of patients >50 years, eGFR increased 11.4% in telbivudine compared to -2.4% decrease in lamivudine-treated patients. Patients with baseline eGFR 60–90 ml/min/1.72m2 eGFR increased by 16.8% in telbivudine versus 3.9% n telbivudine versus treated group. eGFR improvements at 2 years were independent of baseline HBeAg status, markers of virologic response, including HBVDNA undetectable (<300 copies/ml), HBVDNA suppression (<5 logs) or virologic breakthrough/genotypic resistance at 2 years. Patients who had not achieved on-treatment HBeAg seroconversion (17.6%) or HBeAg loss (18.7%) had higher eGFR increase versus patients with HBeAg seroconversion (7.3%, p = 0.0223) or HBeAg loss (6.2%, p = 0.0035). In the stepwise regression model, no differences were observed for: baseline HBeAg status, baseline ALT (<2×ULNvs≥2×ULN), baseline HBVDNA (<9vs≥9log for HBeAg+ and <7vs≥7log for HBeAg− patients), Genotype C and undetectable HBVDNA at Week24. Telbivudine treatment (Odds ratio (OR) 2.509 (95% CI=1.663, 3.784) p<0.0001) and age (continous variable) OR 0.940 (0.923, 0.958), p = 0.0001 were the strongest significant predictors of eGFR increase. Other predictors were Caucasian race (vs Asian), OR 0.338 (0.175, 0.652), p = 0.0012 and Other vs Asian, OR 0.429 (0.183, 1.005), p = 0.0514. Conclusion: In this subanalysis of the GLOBE study, the strongest predictors of improvement on renal function during antiviral therapy in patients with compensated CHB were age and telbivudine treatment, the latter effect independent of on-treatment antiviral response.-
dc.languageengen_US
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep-
dc.relation.ispartofJournal of Hepatologyen_US
dc.titleeGFR Improvement In Chronic Hepatitis B Patients With Telbivudine Treatment Is Independent Of Antiviral Activityen_US
dc.typeConference_Paperen_US
dc.identifier.emailLai, CL: hrmelcl@hku.hken_US
dc.identifier.doi10.1016/S0168-8278(13)60747-3-
dc.identifier.hkuros218440en_US
dc.identifier.volume58en_US
dc.identifier.issueSuppl. 1en_US
dc.identifier.spageS302, abstract no. 745en_US
dc.identifier.epageS302, abstract no. 745en_US
dc.publisher.placeNetherlands-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats